miR-29 Family as Epigenetic Regulators of DNMTs in Prostate Cancer and Benign Prostatic Hyperplasia
Indonesian Biomedical Journal, cilt.17, sa.2, ss.134-142, 2025 (ESCI, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 17 Sayı: 2
- Basım Tarihi: 2025
- Doi Numarası: 10.18585/inabj.v17i2.3456
- Dergi Adı: Indonesian Biomedical Journal
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
- Sayfa Sayıları: ss.134-142
- Anahtar Kelimeler: benign prostatic hyperplasia, DNA methyltransferases-3A/3B, epigenetic, miR-29a/b/c, prostate cancer
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Süleyman Demirel Üniversitesi Adresli: Evet
Özet
BACKGROUND: The miR-29 family (miR-29a/b/c) is recognized as a tumor suppressor, directly targeting DNA methyltransferases (DNMTs), key regulators of epigenetic gene silencing. Even though miR-29 has been implicated in tumor progression, its regulatory interaction with DNMT3A/3B, particularly in prostate cancer (PCa), has not been elucidated well. This study was conducted to explore the potential of miR-29a/b/c in targeting DNMT3A/3B in PCa and benign prostatic hyperplasia (BPH), addressing a critical gap in understanding their epigenetic role. METHODS: This study used tissue samples that were taken surgically from 30 subjects that consisted of 15 diagnosed PCa and 15 BPH patients (as the control group), aged between 18–75 years, with urinary system disorders and had a prostate specific antigen (PSA) value between 1.18 and 56.15 ng/dL. The miR-29a/b/c and DNMT3A/3B expressions were measured using quantitative real-time PCR (qRT-PCR). The variations in mean values across groups, the associations between miR-29a/b/c and DNMT3A/3B expression levels parameters, as well as the correlation between miR-29 levels and DNMT3A/3B variables were then statistically analyzed. RESULTS: The expression levels of miR-29a/b/c were significantly downregulated in the PCa subjects compared to the BPH subjects (p<0.05), and negative correlations were observed between miR-29a/b/c and DNMT3A/3B in the PCa subjects (p<0.001). In addition, a significant inverse correlation was detected only between miR-29a and DNMT3B in BPH subjects (p<0.05). CONCLUSION: The results of this study indicated that miR-29a/b/c in PCa may act as a negative regulator directly targeting DNMT3A/3B. These findings support the role of miR-29s in developing miRNA-based strategies for treating PCa.